Sign In
Buy EFTR
$0.0006
+0 (+0%)
At Close: Jun 03, 2026
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
04:05pm, Monday, 29'th Jan 2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation re
eFFECTOR Therapeutics Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
08:00am, Thursday, 25'th Jan 2024
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) (the “Company”), a leader in the development of selective translation re
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
08:05am, Tuesday, 09'th Jan 2024
- Summary of development progress for tomivosertib and zotatifin and a preview of anticipated 2024 milestones- - Review of recently announced interim data from dose escalation and Phase 2 expansio
eFFECTOR Therapeutics Announces Reverse Stock Split
08:00am, Tuesday, 09'th Jan 2024
EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024 EFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024
Median progression free survival (mPFS) of 7.4 months in the ZFA expansion cohort evaluating zotatifin in combination with fulvestrant and abemaciclib in heavily pretreated patients
Designation is for 2 nd or 3 rd line treatment of patients with disease progression following treatment with endocrine therapy and a CDK 4/6 inhibitor
3 Top Penny Stocks To Watch Before Next Week
02:12pm, Thursday, 16'th Nov 2023
Have you ever thought about diving into penny stocks? These are the stocks that won't break the bank, typically trading for less than $5.
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (
eFFECTOR Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
04:14pm, Monday, 13'th Nov 2023
Management intends to provide an update on its zotatifin clinical development program in estrogen receptor-positive (ER+) metastatic breast cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
08:00am, Monday, 06'th Nov 2023
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (
4 Hot Penny Stocks To Watch With Big News This Week
09:02am, Tuesday, 24'th Oct 2023
Whether you're trading penny stocks or stocks over $100, the goal is the same. You want to find opportunities as early as possible and capitalize.
Trial designed to capitalize on previously published results that showed preclinical activity of tomivosertib in AML models Trial designed to capitalize on previously published results that showed pre
3 Promising Biotech Stocks That Will Make Early Investors Rich
03:07pm, Monday, 02'nd Oct 2023
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeuti
Best Penny Stocks To Buy Now? 10 Under $1 To Watch
11:42am, Monday, 28'th Aug 2023
The traditional approach to investing is finding well-established companies, investing in them and waiting years for a return of 50%. But in today's fast-paced stock market, retail traders are finding
7 Best Penny Stocks To Buy Under $1 in 2023: Big Risk, Big Return?
11:06am, Friday, 25'th Aug 2023
Penny stocks, often priced under $1, have long been the allure for many investors seeking high-risk, high-reward opportunities. These stocks, typically from smaller companies, offer the tantalizing po
